

14 May 2025

Melissa Kostopoulos
Compliance Adviser, Listings Compliance
ASX Limited
525 Collins Street, Rialto, South Tower
ListingsComplianceMelbourne@asx.com.au.

Dear Melissa,

Mayne Pharma Group Limited ('MYX' or 'Mayne Pharma'): Price Query

We refer to your letter dated 14 May 2025 in relation to the change in price of MYX's securities from a high of \$6.790 at close of trade yesterday to a low of \$5.970 today, and the significant increase in the volume of MYX's securities traded today.

- 1. Is MYX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

Noting our response to Question 3 below, MYX is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.

- 2. If the answer to question 1 is "yes".**
 - a. Is MYX relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in MYX's securities would suggest to ASX that such information may have ceased to be confidential and therefore MYX may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.**
 - b. Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).**
 - c. If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?**

Not applicable.

- 3. If the answer to question 1 is "no", is there any other explanation that MYX may have for the recent trading in its securities?**

MYX is aware that on 12 May 2025 (US time) the US Food and Drug Administration (**FDA**) published on its website an 'untitled letter' received by Mayne Pharma on 28 April 2025 (US time) related to certain promotional claims used in a speaker presentation for NEXTSTELLIS® (**FDA Untitled Letter**).

MYX notes that the bidder in relation to the recently announced Scheme of Arrangement was made aware of the FDA Untitled Letter shortly following its date of issue and the FDA Untitled



Mayne Pharma Group Limited
ABN 76 115 832 963
maynepharma.com

T +61 8 8209 2666 **F** +61 8 8281 0284
1538 Main North Road, Salisbury South, SA 5106 Australia
PO Box 700, Salisbury, SA 5108 Australia



You deserve tomorrow.

Letter was made publicly available by the FDA on the 'untitled letters' section of its website on 12 May 2025 (US time).

MYX can only assume that the recent trading is due to market speculation about the perceived implications of the FDA Untitled Letter being received by a company such as MYX. MYX's view is that in and of itself, the FDA Untitled Letter is not materially price sensitive and MYX confirms that it has a near finalised response to the FDA Untitled Letter which it proposes to provide to the FDA within the prescribed timeframe.

Having said that, given the market movement, MYX is comfortable making a further announcement to the market addressing speculation related to the FDA Untitled Letter.

4. Please confirm that MYX is complying with the Listing Rules and, in particular, Listing Rule 3.1.

Confirmed.

5. Please confirm that MYX's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of MYX with delegated authority from the board to respond to ASX on disclosure matters.

Confirmed.

Yours sincerely,

Laura Loftus
Company Secretary
laura.loftus@maynepharma.com



14 May 2025

Reference: 109209

Ms Laura Loftus
Company Secretary
Mayne Pharma Group Limited
1538 Main Road
Salisbury South
South Australia, 5106

By email: laura.loftus@maynepharma.com

Dear Ms Loftus

Mayne Pharma Group Limited ('MYX'): Price - Query

ASX refers to the following:

- A. The change in the price of MYX's securities from a high of \$6.790 at close of trade yesterday to a low of \$5.970 today.
- B. The significant increase in the volume of MYX's securities traded today.

Request for information

In light of this, ASX asks MYX to respond separately to each of the following questions and requests for information:

- 1. Is MYX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
- 2. If the answer to question 1 is "yes".
 - (a) Is MYX relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in MYX's securities would suggest to ASX that such information may have ceased to be confidential and therefore MYX may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
- 3. If the answer to question 1 is "no", is there any other explanation that MYX may have for the recent trading in its securities?
- 4. Please confirm that MYX is complying with the Listing Rules and, in particular, Listing Rule 3.1.
- 5. Please confirm that MYX's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of MYX with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:00 PM AEST Wednesday, 14 May 2025**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, MYX's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require MYX to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsComplianceMelbourne@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in MYX's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in MYX's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to MYX's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that MYX's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Regards

ASX Compliance